- Diseases
- Acoustic Neuroma (14)
- Adrenal Gland Tumor (24)
- Anal Cancer (66)
- Anemia (2)
- Appendix Cancer (16)
- Bile Duct Cancer (28)
- Bladder Cancer (68)
- Brain Metastases (28)
- Brain Tumor (230)
- Breast Cancer (716)
- Breast Implant-Associated Anaplastic Large Cell Lymphoma (2)
- Cancer of Unknown Primary (4)
- Carcinoid Tumor (8)
- Cervical Cancer (154)
- Colon Cancer (164)
- Colorectal Cancer (110)
- Endocrine Tumor (4)
- Esophageal Cancer (42)
- Eye Cancer (36)
- Fallopian Tube Cancer (6)
- Germ Cell Tumor (4)
- Gestational Trophoblastic Disease (2)
- Head and Neck Cancer (6)
- Kidney Cancer (124)
- Leukemia (344)
- Liver Cancer (50)
- Lung Cancer (288)
- Lymphoma (284)
- Mesothelioma (14)
- Metastasis (30)
- Multiple Myeloma (98)
- Myelodysplastic Syndrome (60)
- Myeloproliferative Neoplasm (4)
- Neuroendocrine Tumors (16)
- Oral Cancer (100)
- Ovarian Cancer (170)
- Pancreatic Cancer (166)
- Parathyroid Disease (2)
- Penile Cancer (14)
- Pituitary Tumor (6)
- Prostate Cancer (144)
- Rectal Cancer (58)
- Renal Medullary Carcinoma (6)
- Salivary Gland Cancer (14)
- Sarcoma (236)
- Skin Cancer (296)
- Skull Base Tumors (56)
- Spinal Tumor (12)
- Stomach Cancer (60)
- Testicular Cancer (28)
- Throat Cancer (90)
- Thymoma (6)
- Thyroid Cancer (98)
- Tonsil Cancer (30)
- Uterine Cancer (78)
- Vaginal Cancer (14)
- Vulvar Cancer (18)
- Cancer Topic
- Adolescent and Young Adult Cancer Issues (20)
- Advance Care Planning (10)
- Biostatistics (2)
- Blood Donation (18)
- Bone Health (8)
- COVID-19 (362)
- Cancer Recurrence (120)
- Childhood Cancer Issues (120)
- Clinical Trials (624)
- Complementary Integrative Medicine (24)
- Cytogenetics (2)
- DNA Methylation (4)
- Diagnosis (230)
- Epigenetics (6)
- Fertility (64)
- Follow-up Guidelines (2)
- Health Disparities (14)
- Hereditary Cancer Syndromes (122)
- Immunology (18)
- Li-Fraumeni Syndrome (8)
- Mental Health (118)
- Molecular Diagnostics (8)
- Pain Management (62)
- Palliative Care (8)
- Pathology (10)
- Physical Therapy (18)
- Pregnancy (18)
- Prevention (894)
- Research (390)
- Second Opinion (74)
- Sexuality (16)
- Side Effects (604)
- Sleep Disorders (10)
- Stem Cell Transplantation Cellular Therapy (216)
- Support (404)
- Survivorship (322)
- Symptoms (184)
- Treatment (1774)
First-of-its-kind study examines cosmetic outcomes for older breast cancer patients
2 minute read | Published January 12, 2017
Medically Reviewed | Last reviewed by an MD Anderson Cancer Center medical professional on January 12, 2017
In the first study evaluating patient-reported cosmetic outcomes in older women with breast cancer, MD Anderson researchers found that less radiation was associated with improved cosmetic satisfaction long-term. However, reduced radiation was also associated with a slightly increased risk of disease recurrence.
Like younger patients, older women with early-stage breast cancer have a number of treatment options, including: lumpectomy and whole breast irradiation, lumpectomy plus brachytherapy, lumpectomy alone, mastectomy without radiation, and mastectomy plus radiation. However, cosmetic and other quality-of-life outcomes associated with these treatments have not been compared in this age population.
“There’s very little in the literature about how older patients report their outcomes – either they were not included in previous studies, or were not asked about their cosmetic satisfaction. With our study, we wanted to survey women to better understand their long-term cosmetic satisfaction, and compare satisfaction across local therapy strategies,” says Cameron Swanick, a Radiation Oncology resident who led the trial.
The study builds on research published in 2012 by Benjamin Smith, M.D., which found that accelerated partial breast irradiation (APBI) brachytherapy is associated with a higher rate of later mastectomy, increased radiation-related toxicities and post-operative complications, compared to traditional whole-breast irradiation.
“We need treatment that is gentler than whole breast radiation, but provides broader of coverage than brachytherapy,” says Smith. “There are plenty of hints in the literature that indicate there’s a happy medium in between these two treatments, and that’s probably the sweet spot for many breast cancer patients.”
